CD8A and neoplasm: Mice treated with high-doseR.E­(IT) and R.E@MN showed significant tumor inhibition and prolongedsurvival, with overall survival rates of 60% beyond 40 days (FigureS7B–D, Supporting Information).Flow cytometry revealed an increase in CD8+ T cell infiltrationin both the tumor and TDLN following MN treatment (Figure S8, Supporting Information), suggesting that R.E@MNenhances tumor-specific immune responses.